Puslapis 1 nuo 66 rezultatus
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention is in the field of cannabis active compound formulation for medicinal application. Specifically, the use of formulations containing cannabis-derived compounds as medical treatments for chronic pain.
Discussion of the State of
FIELD OF THE INVENTION
The present invention relates to a therapeutic method for the treatment of diseases connected with the modulation of the cannabinoid peripheral receptor, comprising administering amidic derivatives of mono and bicarboxylic acids with substituted aminoalcohols or
FIELD
The present invention relates to compounds by the regulation of cannabinoid receptors. More specifically, the compounds are inverse antagonists of cannabinoid receptor subtype-2, otherwise known as CB2.
BACKGROUND
Osteoporosis is a major metabolic bone disease that affects 44 million Americans
FIELD
The present invention relates to compounds by the regulation of cannabinoid receptors. More specifically, the compounds are inverse antagonists of cannabinoid receptor subtype-2, otherwise known as CB2.
BACKGROUND
Osteoporosis is a major metabolic bone disease that affects 44 million Americans
FIELD OF THE INVENTION
The present invention relates to the field of cannabinoids. More specifically, the present invention describes the medical use of some quinonoid derivatives of cannabinoids, as well as some such novel compounds.
BACKGROUND OF THE INVENTION
All publications mentioned throughout
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to flavonoid derivatives and, more particularly, to cannabis flavonoid derivatives or the pharmaceutically acceptable salt thereof that may be used in a pharmaceutical composition for preventing and treating ocular
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to flavonoid derivatives and, more particularly, to cannabis flavonoid derivatives or the pharmaceutically acceptable salt thereof that may be used in a pharmaceutical composition for preventing and treating ocular
FIELD OF THE INVENTION
The present invention relates to therapeutics, and more especially cannabis based therapeutics for use in treating those known to have or be at increased risk of endometriosis and other ailments.
BACKGROUND OF THE INVENTION
Endometriosis is a common gynecological disorder.
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention is in the field of therapeutic uses of the cannabis plant, and more specifically the field of therapeutic smokable products derived from cannabis.
Discussion of the State of the Art
Recently, multiple states have passed
FIELD OF THE INVENTION
This invention relates generally to cannabinoid compounds. One embodiment of the present invention more particularly relates to cannabinoid compounds exhibiting fluorescence properties, particularly in the ultraviolet-visible wavelength ranges.
BACKGROUND OF THE INVENTION
The
BACKGROUND
Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression,
BACKGROUND OF THE INVENTION
Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite,
BACKGROUND
Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression,
BACKGROUND
Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression,
BACKGROUND OF THE INVENTION
Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite,